Malignant Esophageal Neoplasm

Antitumour effect of alisertib treatment in esophageal adenocarcinomas can be intensified in combination with cisplatin.

PMID 22302096 · Sehdev et al., 2012 · Open in CIViC

A retrospective study examining the expression of AURKA in tumor samples of 78 esophageal squamous cell carcinoma patients found that positive expression of AURKA (>10% of cells by IHC) was correlated… (full text at CIViC)

PMID 25924824 · Tamotsu et al., 2015 · Open in CIViC

The efficacy of novel AURKA inhibitor alisertib (MLN8327) was tested alone or in combination with cisplatin in three esophageal adenocarcinoma cell lines (FLO-1, OE19 and OE33) that overexpress AURKA.… (full text at CIViC)

PMID 22302096 · Sehdev et al., 2012 · Open in CIViC

Immunohistochemical analysis of tumors from 116 esophageal squamous cell carcinoma found that expression of AXL was associated with increased progression of the tumor (P < 0.0001), increased risk of d… (full text at CIViC)

PMID 27172793 · Hsieh et al., 2016 · Open in CIViC

Cyclin-dependent kinase 9 (CDK9) was predominantly overexpressed in esophageal carcinoma tumor samples compared to normal esophageal cell lines. This high expression was also found in 90% of invasive … (full text at CIViC)

PMID 28404924 · Tong et al., 2017 · Open in CIViC

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. The TC/CC genotype of p14ARF at rs3814960 had decreased overall survival (HR = 2.77, 95% CI: 1.3… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

In patients with Barrett's adenocarcinoma, those with amplification of EGFR had shorter disease-specific survial.

PMID 20840671 · Marx et al., 2010 · Open in CIViC

This retrospective preclinical study assessed the efficacy of afatinib towards esophageal squamous cell carcinoma (ESCC) cell lines expressing EGFR L861Q mutation. In one experiment, a ESCC KYSE270 EG… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

55 tumor samples were analyzed for EGFR expression using IHC. PFS and OS was shorter for the EGFR high expressing group (18 pts) than for the low to moderate expression group (37 pts). PFS: 5.8 ± 0.5 … (full text at CIViC)

PMID 26459251 · Jia et al., 2016 · Open in CIViC

Expression of EGFR in 55 samples of esophageal squamous cell carcinoma with IHC was not predictive of response to EGFR inhibitor nimotuzumab. EGFR overexpression was related to poor OS and PFS.

PMID 26459251 · Jia et al., 2016 · Open in CIViC

In an in vitro study, an esophageal squamous cell carcinoma cell line KYSE70 expressing EGFR Y69fs*11 mutation was associated with insensitivity to erlotinib treatment (IC50=4.31uM). Resistance was de… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

Mutations in histone modifier genes were analyzed in exome sequence data from 113 esophageal squamous cell carcinoma tumors. KYSE-150 and KYSE-450 ESCC cell lines were depleted of EP300 using shRNA, t… (full text at CIViC)

PMID 25151357 · Gao et al., 2014 · Open in CIViC

This study found the clinical BTK/ERBB2 kinase inhibitor, ibrutinib, downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle a… (full text at CIViC)

PMID 28830912 · Chong et al., 2018 · Open in CIViC

In an in vitro study, an esophageal squamous cell carcinoma (ESCC) cell line KYSE150 expressing ERBB3 (HER3) D297Y mutation was associated with insensitivity to cetuximab, afatinib, and erlotinib trea… (full text at CIViC)

PMID 27207775 · Nakamura et al., 2016 · Open in CIViC

In this report, Mizukami et al. explored major FGFR1, FGFR2, and FGFR3 fusion transcripts in ESCC and GC specimens (n = 74 and 114, respectively) using a most comprehensive next-generation sequencing … (full text at CIViC)

PMID 27771611 · Mizukami et al., 2017 · Open in CIViC

Overall, 63% of the patients in the T-allele group (TT + CT), i.e with the T393C genotype, were minor responders with more than 10% residual vital tumor cells in resection specimens, whereas T(-) geno… (full text at CIViC)

PMID 19274060 · Alakus et al., 2009 · Open in CIViC

HDAC expression was assessed from 27 esophageal squamous cell carcinoma (ESCC) cell lines to determine the efficacy of HDAC inhibitors and found that practically all 10 HDAC (HDAC1, HDAC2, HDAC3, HDAC… (full text at CIViC)

PMID 30484863 · Cheng et al., 2018 · Open in CIViC

In 62 esophageal carcinoma tumor samples, HDAC1 expression was found to considerably increase by 82% compared to adjacent non-tumor tissues with (18.2%) and identified as HDAC1 positive. HDAC1 positiv… (full text at CIViC)

PMID 31908417 · Zhu et al., 2019 · Open in CIViC

Two human esophageal squamous cell carcinoma cell lines, KYSE170 and TE13, were transfected with the IL6 gene. These cell lines produced 5-6 fold (KYSE170) and 16-17 fold (TE13) IL6 compared to contr… (full text at CIViC)

PMID 21273582 · Suchi et al., 2011 · Open in CIViC

124 esophageal squamous cell carcinoma patients with radical resection were genotyped using MassArray. Patients with the DEL/A +AA genotype of MDM2 rs34886328 had a notably increased overall survival… (full text at CIViC)

PMID 27414035 · Li et al., 2016 · Open in CIViC

A total of 185 patients with stage III or IV esophageal + junctional cancers were tested for amplified genes in this retrospective study. There were 5 MET amplifications, 14 EGFR amplifications, and 1… (full text at CIViC)

PMID 22042947 · Lennerz et al., 2011 · Open in CIViC

This study found the clinical BTK/ERBB2 kinase inhibitor, ibrutinib, downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle a… (full text at CIViC)

PMID 28830912 · Chong et al., 2018 · Open in CIViC

Collectively data from expression analysis of 102 esophageal squamous cell carcinoma (ESCC) sample tissues established MYC and HSP90 as potential targets with overexpression of MYC observed in over ha… (full text at CIViC)

PMID 32308431 · Guan et al., 2020 · Open in CIViC

A 71-year-old male with esophageal carcinoma harboring NTRK1 amplification, based on FoundationOne CDx profiling test, was treated with larotrectinib. Treatment with larotrectinib led to a shrinkage o… (full text at CIViC)

PMID 32323889 · Hempel et al., 2020 · Open in CIViC

In a retrospective study of patients with esophageal carcinoma, those with mutations in TP53 had worse overall survival.

PMID 19941080 · Yamasaki et al., 2010 · Open in CIViC

Analysis of 77 esophageal squamous cell carcinoma tumor and normal samples for germline mutations revealed a rare TP53 V197E variant in a single patient. The V197E mutation is in the DNA-binding domai… (full text at CIViC)

PMID 30833958 · Deng et al., 2019 · Open in CIViC

Patients with p53 wild type (as defined by low expression and/or wild-type tp53 gene) had a higher response rate to chemotherapy-based treatment (total major response [MR]: risk ratio [RR] = 1.09, 95 … (full text at CIViC)

PMID 23515910 · Zhang et al., 2013 · Open in CIViC

Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC)

PMID 31427973 · Bi et al., 2019 · Open in CIViC

YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC)

PMID 25739674 · Song et al., 2015 · Open in CIViC

YAP1 up-regulation of EGFR plays an important role in conferring therapy resistance to 5-FU or docetaxel in esophageal cancer (EC) cells. Inhibitor of YAP1, Verteporfin, can overcome the acquired chem… (full text at CIViC)

PMID 25739674 · Song et al., 2015 · Open in CIViC